Research Topics
| C Chandra KumarSummaryAffiliation: Schering-Plough Research Institute Country: USA Publications
| Collaborators
|
Detail Information
Publications
Chloramine T-induced structural and biochemical changes in echistatinC C Kumar
Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, NJ 07033, USA
FEBS Lett 429:239-48. 1998..These structural changes in echistatin help explain the changes in the binding characteristics of the molecule following chloramine T reaction...- SCH 51344, an inhibitor of RAS/RAC-mediated cell morphology pathwayC C Kumar
Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
Ann N Y Acad Sci 886:122-31. 1999.... - Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonistC C Kumar
Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
Cancer Res 61:2232-8. 2001..Finally, SCH 221153 exerted a significant inhibition on tumor growth induced by intradermal or s.c. injection of human melanoma LOX cells in severe combined immunodeficient mice... - Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signalingC C Kumar
Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, NJ 07033, USA
Biochim Biophys Acta 1526:257-68. 2001..However, the ATP binding regions are highly conserved in the three isoforms of Akt implying that the discovery of isoform-selective inhibitors would be very challenging... - Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesisC Chandra Kumar
Department of Tumor Biology, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
Curr Drug Targets 4:123-31. 2003..Thus alphavbeta3 may prove to be an important target for pharmacological intervention in more than one clinical setting... - AKT crystal structure and AKT-specific inhibitorsChandra C Kumar
Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, NJ 07033, USA
Oncogene 24:7493-501. 2005..The issues and challenges facing the development of different classes of inhibitors as therapeutics are also discussed... - Adenoviral-mediated expression of a kinase-dead mutant of Akt induces apoptosis selectively in tumor cells and suppresses tumor growth in miceAmanda Jetzt
Department of Tumor Biology, Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA
Cancer Res 63:6697-706. 2003..These studies validate the usefulness of targeting Akt for new drug discovery efforts and suggest that inhibition of Akt may have a selective antitumor effect... - Development of a fluorescence polarization bead-based coupled assay to target different activity/conformation states of a protein kinaseZhuomei Lu
Department of Tumor Biology, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
J Biomol Screen 9:309-21. 2004..This coupled assay has the potential to identify compounds that target the inactive form of Akt and prevent its activation by PDK1, in addition to finding inhibitors of PDK1 and activated Akt enzymes... - Transforming growth factor-beta 2 is a transcriptional target for Akt/protein kinase B via forkhead transcription factorAhmed A Samatar
Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
J Biol Chem 277:28118-26. 2002..These results suggest that repression of TGF-beta 2 promoter activity in cells expressing activated Akt may play a role in promoting tumorigenesis and escape from the growth-inhibitory and/or apoptotic effects of TGF-beta...